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1. Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) for hematological 
malignancies was developed in the late 1960s as a way to deliver supra-lethal 
doses of chemotherapy and/or total body irradiation (TBI) with the aim of 
eradicating the underlying disease while marrow was infused to restore hemat-
opoiesis. However, confirming observations made in mice 20 years prior [1], 
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Weiden, et al. recognized in the late 1970s that the allograft itself conferred 
immune-mediated antileukemic effects [2, 3]. Indeed, patients who developed 
acute and/or chronic Graft-versus-Host Disease (GVHD) had lower risks of 
relapse than those who did not [2, 3]. This antileukemic effect of GVHD was 
termed the “Graft-versus-Tumor effect.” The existence of Graft-versus-Tumor 
effects was then supported by several observations demonstrating higher risk 
of relapse in patients given syngeneic HSCT, compared to those receiving 
grafts from allogeneic donors [4] and in those given T cell-depleted grafts [5]. 
Furthermore, it was found that immune-mediated effects of donor lymphocyte 
infusions (DLI) were sufficient to eradicate the malignancy in a number of 
patients who relapsed with chronic or acute myeloid leukemias after allogeneic 
HSCT [6].
The myeloablative doses of chemotherapy and/or TBI given during the 
conditioning regimen for conventional allogeneic HSCT can produce sig-
nificant morbidity and mortality, particularly in older patients, those with 
medical comorbidities, or those who have failed a myeloablative HSCT [7, 8]. 
Because of these toxicities, the use of myeloablative allogeneic HSCT has 
been restricted to younger patients in good medical condition, while median 
patient age at diagnosis for acute or chronic myeloid leukemia, chronic 
lymphocytic leukemia, Non-Hodgkin’s Lymphoma and multiple myeloma 
ranges from 65 to 71 years [SEERS (surveillance, Epidemiology and End 
Results) data [9] ].
2. Nonmyeloablative and Reduced-Intensity Conditioning
Given the increasingly recognized power of Graft-versus-Tumor effects, 
several groups of investigators explored the feasibility of nonmyeloablative 
or reduced-intensity conditioning regimens that would allow engraftment of 
both donor hematopoietic stem cells and donor T cells, and then eradicate 
the malignancies mainly towards Graft-versus-Tumor effects [10–16] . While 
Giralt, et al. proposed criteria for reduced-intensity conditioning {1) reversible 
myelosuppression within 28 days without stem cell support, 2) mixed chimerism 
(i.e., coexistence of hematopoietic cells of donor and host origin) in a proportion 
of patients at time of first assessment, and 3) low rates of non-hematologic 
toxicity)} [17], practical definitions for reduced-intensity conditioning regimen 
varied from one study to another (Table 17-1).
Further, separating what constitutes a nonmyeloablative versus a reduced-
intensity conditioning has been somewhat arbitrary (Fig. 17-1). Reduced-intensity 
conditioning regimens have combined fludarabine (used mainly for its 
immunosuppressive activity) with consequent (but nonmyeloablative) doses 
of alkylating agents such as melphalan (140 mg/m2) [18], thiotepa 
(≤ 10 mg/kg) or busulfan (4–8 mg/kg) [19], given to produce significant 
antitumor effects with the objective of both debulking and controlling the 
malignancy before the occurrence of Graft-versus-Tumor effects. In contrast, 
nonmyeloablative conditionings have used potent immunosuppressive regimens 
to overcome Host-versus-Graft reactions (graft rejection) [15, 16, 20], allowing 
engraftment of donor hematopoietic and immune cells, and eradication of 
host-derived hemato poiesis and tumor cells almost exclusively via Graft-
versus-Tumor effects. The distinction of what constitutes a nonmyeloablative 
and what constitutes a reduced-intensity conditioning is clinically relevant 
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Table 17-1. Practical definitions for reduced-intensity conditioning.
CIBMTR/NMDP [17]
 • ≤ 5 Gy TBI
 • ≤ 9 mg/kg total busulfan dose
 • ≤ 140 mg/m3 total melphalan dose
 • ≤ 10 mg/kg total thiothepa dose
 • usually includes a purine analog
EBMT (1) [82]
Fludarabine associated with:
 • ≤ 4 Gy TBI
 • ≤ 10 mg/kg total busulfan dose
 • ≤ 140 mg/m2 total melphalan dose
 • ≤ 10 mg/kg total thiotepa dose
EBMT (2) [46]
Fludarabine associated with:
 • < 3 Gy TBI
 • ≤ 8 mg/kg busulfan
 • or other nonmyeloablative drugs
CIBMTR, Center for International Blood and Marrow Research; NMDP, National Marrow Donor 
Program; EBMT, European Group for Blood and Marrow Transplantation; TBI, total body irradiation
Fig. 17-1. Commonly used conditioning regimens in relation to their immunosuppres-
sive and myelosuppressive properties Please note that this classification is not based on 
direct experimentation and is, thus, hypothetical TBI, total body irradiation; TLI, total 
lymphoid irradiation; F, fludarabine; Cy, cyclophosphamide; Cy 120, cyclophosphamide 
120 mg/kg; Cy 200, cyclophosphamide 200 mg/kg; M, melphalan, M 140; melphalan 
140 mg/m2; M 180; melphalan 180 mg/m2; Flag-Ida, fludarabine/cytosine arabinoside/
idarubicin; TT, thiotepa; ATG, anti-thymocyte globulin; Ale, alemtuzumab; Bu8, busul-
fan 8 mg/kg; Bu16, busulfan 16 mg/kg. Reprinted from Molecular Therapy, 12:26–41, 
copyright 2006: F. Baron and R. Storb, “Allogeneic hematopoietic cell transplantation 
following nonmyeloablative conditioning as treatment for hematologic malignancies and 
inherited blood disorders (Review),” with permission from Elsevier
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since nonmyeloablative conditioning has been associated with a lower degree 
of donor engraftment, higher risk of graft rejection, decreased risk of non-
relapse mortality, and higher risk of relapse compared with reduced-intensity 
regimens as observed in a study performed at the M.D. Anderson Cancer 
Center (MDACC) [21].
3. Engraftment Kinetics
By definition, nonmyeloablative and reduced-intensity conditioning regimens 
usually lead to an initial state of mixed chimerism [22]. Several factors have 
been associated with kinetics of donor engraftment after nonmyeloablative 
conditioning. Factors associated with faster donor T cell engraftment included 
high intensity of the conditioning regimen [21, 22], having had previous 
myelosuppressive chemotherapy [23, 24], the use of peripheral blood stem 
cells (PBSC) instead of marrow as a stem cell source [25–27], a high number 
of CD34+ and T cells in the graft [23, 26, 27], and intense post-grafting immunosup-
pression [28].
High levels (>50%) of donor T and NK-cell chimerism one month after 
HSCT have each been associated with a lower risk of graft rejection [15, 24]. 
When analyzed as a continuous variable, higher levels of donor T cell chimerism 
one month after HSCT were associated with increased risks of grade II–IV 
acute GVHD [24] (Fig. 17-2A). Further, achievement of full donor T cell 
chimerism was associated with a lower risk of relapse (Fig. 17-2B). Finally, in 
patients with acute myeloid leukemia and myelodysplastic syndromes, the risk 
of subsequent relapse was substantially higher in patients with < 90 percent 
donor chimerism levels among marrow CD34+ cells on day 28 after HSCT 
than in those with > 90 percent [29].
4. Transplant-Related Toxicities after Nonmyeloablative 
versus Myeloablative Conditioning
Transplant-related toxicities and infections occurring after myeloablative 
allogeneic HSCT have been thought to be the consequence of the intense condi-
tioning, of Graft-versus-Host reactions, or of both. A number of retrospective 
studies compared transplant-related toxicities and infections after HSCT follow-
ing nonmyeloablative versus myeloablative conditioning with to determine the 
relative contributions of conditioning intensity to these complications.
Not unexpectedly, the hematological changes after nonmyeloablative condi-
tioning were milder than that seen after myeloablative conditioning [30], and 
patients given nonmyeloablative or reduced-intensity conditioning required 
less platelet and red blood cell transfusions than those given myeloablative 
conditioning (reviewed in reference [31]). Similarly, liver, kidney, gastroin-
testinal, and lung toxicities were significantly reduced with nonmyeloablative 
conditioning [32–35].
Junghanss, et al. compared the incidence of post-transplant infections in 56 
nonmyeloablative recipients to that in 112 matched controls given myeloabla-
tive conditioning [36, 37]. The 30- and 100-day incidences of bacteremia were 
9 percent and 27 percent in nonmyeloablative recipients versus 27 percent 
(P=0.01) and 41 percent (P=0.07) in myeloablative recipients, respectively. 
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In contrast, invasive aspergillosis occurred at a similar rate (15% versus 9% 
at one year; P=0.30). The onset of CMV disease was significantly delayed 
among nonmyeloablative compared to myeloablative recipients (medians of 
130 versus 52 days; P=0.02) due to the persistence of host-derived CMV 
immunity early after HSCT in nonmyeloablative recipients [38]. However, the 
one-year probability of CMV disease for high risk CMV patients was compa-
rable in the two groups.
Fig. 17-2 A. Cumulative incidence of grade II–IV acute GVHD (P<0.0001) accord-
ing to day 28 donor T cell chimerism levels in 322 patients reported in ref. [54] given 
grafts after 2 Gy TBI with or without fludarabine B) Cumulative incidence of relapse 
according to day 84 donor T cell chimerism levels in patients reported in ref. [54] 
given grafts after 2 Gy TBI with or without fludarabine (P=0.002) Reprinted with 
permission F. Baron and B.M. Sandmaier, “Chimerism and outcomes after allogeneic 
hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia 
2006; 20:1690–1700
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5. Graft-versus-Host Disease and Graft-versus-Tumor 
Effects After Nonmyeloablative Conditioning
The biology of reconstitution of donor-derived immunity after nonmyeloabla-
tive conditioning differs from what occurs after myeloablative conditioning 
in several aspects. First, nonmyeloablative conditionings generally lead to 
an initial state of mixed donor-host chimerism that might favor both Host-
versus-Graft and Graft-versus-Host tolerance and, thus, limit GVHD [39]. 
Secondly, the intensity of the preparative regimens has been shown to contribute 
to acute GVHD physiopathology, presumably by inducing tissue damage 
and the release of a “cytokine storm” [40, 41]. In contrast, the number of 
recipient-derived antigen presenting cells (APC) might be higher after non-
myeloablative than myeloablative conditioning. Since recipient-derived APC 
are thought to play a major role in the initiation of acute GVHD [42], their 
persistence in an increased number after nonmyeloablative regimen might 
favor acute GVHD.
A number of reports have compared incidences of acute and chronic GVHD 
after nonmyeloablative or reduced-intensity conditioning. Most have shown 
lower incidences of acute GVHD and similar or lower incidences of chronic 
GVHD after nonmyeloablative versus myeloablative conditioning [43–47], 
including one study analyzing age-matched patients treated in a single institu-
tion [43]. However, although relatively less frequent, GVHD with or without 
associated infections has remained the leading cause of non-relapse mortality 
after nonmyeloablative HSCT.
GVHD incidence could be decreased by the use of anti-thymocyte globulin 
(ATG) or alemtuzumab, a humanized monoclonal antibody recognizing CD52 
that is expressed on lymphocytes and NK cells, but not on hematopoietic stem 
cells [12, 20, 48]. However, these strategies were associated with increased 
risk of disease relapse/progression [48, 49].
Another approach aimed at reducing the incidence of acute GVHD has been 
developed by the Stanford University group. Based on murine experiments 
[50], the authors investigated a novel nonmyeloablative regimen that favored 
the presence of a high proportion of regulatory NK-T cells [50]. This regimen 
consisted of total lymphoid irradiation (TLI, 8 Gy) and ATG (Thymoglobulin, 
7.5 mg/kg total dose), and post-grafting immunosuppression with MMF and 
CSP. First results in 37 patients with various hematological malignancies indi-
cated that this regimen was indeed associated with a low incidence of grade 
II–IV acute GVHD (one of 37 patients), while Graft-versus-Tumor effects were 
apparently preserved [20].
As mentioned earlier, GVHD occurrence is strongly associated with Graft-
versus-Tumor effects in patients given myeloablative conditioning [3]. Since 
nonmyeloablative regimens rely nearly exclusively on Graft-versus-Tumor 
effects for tumor eradication, several groups of investigators looked at the 
impact of GVHD on HSCT outcomes after nonmyeloablative or reduced-
intensity conditioning.
First, Martino, et al. showed that patients with acute myeloid leukemia 
(n=17) or myelodysplastic syndrome (n=20) who experienced acute and/or 
chronic GVHD had significantly lower risks of relapse than those who did not 
(P=0.008) [51]. Kroger, et al. analyzed data from 120 patients with multiple 
soiffer_Chap17.indd   350 3/30/2008   5:25:22 PM
Un
co
rre
ct
ed
 P
ro
of
Chapter 17 Nonmyeloablative HSCT 351
myeloma who were given allogeneic grafts after reduced-intensity condition-
ing [52]. While occurrence of acute GVHD was found to have no impact on 
relapse risks, occurrence of chronic GVHD was associated with significantly 
lower risk of relapse (P=0.02) in a time-dependent Cox analysis [52]. Similar 
observations were made by Crawley, et al. in a cohort of patients given 
allogeneic grafts after nonmyeloablative or reduced-intensity conditioning 
at various European Group for Blood and Marrow Transplantation (EBMT)-
affiliated centers as treatment for multiple myeloma [49]. More recently, Blaise, 
et al. analyzed outcomes of 33 patients with acute myeloid leukemia in first 
complete remission receiving allogeneic HSCT from HLA-identical siblings 
following reduced-intensity conditioning [53]. In a landmark analysis starting 
on day 100, occurrence of chronic GVHD was associated with a lower risk 
of relapse (0% versus 44%, P=0.007) and better leukemia-free survival (95% 
versus 53%, P=0.007).
We analyzed the impact of acute and chronic GVHD on HSCT outcomes in 
a cohort of 322 patients given nonmyeloablative HSCT as treatment for hema-
tological malignancies [54]. Grades II and III–IV acute GVHD were not sig-
nificantly associated with lower risks of progression/relapse, but were instead 
associated with increased non-relapse mortality and lower progression-free 
survival. In contrast, the occurrence of chronic GVHD correlated with a lower 
risk of relapse in multivariate time-dependent analyses (HR=0.4, P=0.006) and 
was associated with significantly better progression-free survival (HR=0.5, 
P=0.003) (Fig. 17-3).
Taken together, these observations suggested that new approaches aimed 
at reducing the incidence of grade II–IV acute GVHD without suppressing 
chronic GVHD might improve progression-free survival after nonmyeloabla-
tive or reduced-intensity conditioning.
Fig. 17-3. Impact of acute and chronic GVHD and of achievement of full donor T cell 
chimerism (FDC) on progression-free survival (PFS) 322 patients reported in ref. [54] 
given grafts after 2 Gy TBI with or without fludarabine
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6. Results in Specific Diseases
Tables 17-2 and 17-3 show the results of a number of phase I–II studies assessing 
post-HSCT outcomes in patients with hematological malignancies who were 
given nonmyeloablative or reduced-intensity conditioning. Since inclusion 
criteria varied between the studies, the efficacy of each regimen cannot be 
compared.
Encouraging results have generally been observed in patients with acute 
myeloid leukemia in first or second complete remissions (two-year overall 
survival ranging from 40% to 75%) [46, 53, 55–57] (Fig. 17-4), as well 
as in patients with myelodysplastic syndrome with < 5 percent blasts at 
HSCT (two-year overall survival ranging from 33% to 60%) [58, 59], 
chronic myeloid leukemia (two-year overall survival ≥ 70% for patients in 
first chronic phase [10, 60, 61]), chronic lymphocytic leukemia (two-year 
overall survival ranging from 50% to 80%) [62–66] , or indolent or chemo-
therapy-sensitive aggressive Non-Hodgkin’s Lymphoma (two-year overall 
survival ranging from 50% to 80%) [12, 14, 67–70] (Tables 17-2 and 17-3). 
Conversely, results in patients with advanced aggressive diseases (such 
as acute leukemias not in complete remission, chemotherapy-insensitive 
high-grade Non-Hodgkin’s Lymphoma or multiple myeloma, or advanced 
myelodysplastic syndromes) have been less impressive.
7. Consolidative Allografts Following Planned Autografts
Since Graft-versus-Tumor effects may not be sufficiently fast enough to eradi-
cate large volume disease in patients with aggressive malignancies, an elegant 
strategy has been to follow a “debulking” autologous HSCT (which can be 
administered with transplant-related mortality rates of less than 5%) with a 
nonmyeloablative allogeneic HSCT. This strategy, pioneered by Carella, et al. 
in patients with refractory lymphoma [71], was evaluated by Maloney, et al. in 
Fig. 17-4. Overall survival in 122 acute myeloid leukemia patients following nonmy-
eloablative HSCT according to disease status at time of HSCT
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54 patients with multiple myeloma. Patients were first given autologous HSCT 
after a cytoreductive dose of 200 mg/m2 melphalan; this was followed 1.3–7.6 
(median two) months later by allogeneic HSCT from HLA-identical sibling fol-
lowing 2 Gy TBI [72]. The 100-day mortalities after autologous and allogeneic 
HSCT were 2 percent each. Two-year overall and progression-free survivals 
were 78 percent and 55 percent, respectively. A large phase III study comparing 
tandem autologous HSCT with tandem autologous/allogeneic HSCT is cur-
rently ongoing in patients with multiple myeloma (BMT-CTN 01–02).
8. Nonmyeloablative HSCT After Failed Autologous HSCT
The outcomes for patients with relapse or secondary myelodysplastic syn-
dromes after autologous HSCT were poor. A second myeloablative HSCT 
from an allogeneic donor has been a potentially curative option, but this 
approach has been limited by non-relapse mortality rates of 50 to 80 percent 
[8]. This prompted several groups of researchers to investigate the feasibility 
of allogeneic HSCT with nonmyeloablative or reduced-intensity conditioning 
in patients who had failed autologous HSCT. As shown in Table 17-4, most 
studies found lower non-relapse mortality, compared to what was seen following 
myeloablative allogeneic HSCT, and relatively encouraging results in patients 
with chemo-sensitive disease at HSCT [73–79] .
We recently analyzed data from 147 patients who had treatment failure 
with myeloablative autologous (n=135), allogeneic (n=10) or syngeneic (n=2) 
HSCT and underwent HLA-matched related (n=62) or unrelated (n=85) HSCT 
following conditioning with 2 Gy TBI with or without added fludarabine, to 
determine factors that predict HSCT outcomes [80]. Three-year incidences 
of non-relapse mortality, relapse and overall survival were 32 percent, 
48 percent and 27 percent, respectively, for patients given grafts from related 
donors, and 28 percent, 44 percent and 44 percent, respectively, for unrelated 
graft recipients. The best outcomes were seen in patients with Non-Hodgkin’s 
Lymphoma, while patients with Hodgkin’s Lymphoma and multiple myeloma 
had poor outcomes due to high incidences of relapse/progression (Fig. 17-5). 
Being in partial or complete remission at HSCT (P=0.002), and developing 
chronic GVHD (P=0.03) were associated with lower risks of relapse/
progression. Further, being in partial or complete remission at HSCT 
(P=0.01), absence of comorbidity at HSCT (P=0.03) and lack of acute GVHD 
after HSCT (P=0.06) were associated with better overall survival.
9. Outcomes with Myeloablative versus Nonmyeloablative 
Conditioning
Alyea, et al. performed a retrospective analysis of 152 patients (> 50-years-old) 
with hematological malignancies undergoing HSCT after reduced-intensity 
(n=71) or myeloablative (n=81) conditioning [81]. Reduced-intensity condition-
ing consisted of fludarabine (120 mg/m2) and intravenous busulfan (3.2 mg/kg), 
while myeloablative conditioning included mainly cyclophosphamide (3.6 g/m2) 
plus TBI (14 Gy). With a median follow-up of 18 months, the cumulative inci-
dences of relapse and non-relapse mortality were 46 percent and 32 percent, 
respectively, in the reduced-intensity conditioning group, versus 30 percent 
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Fig. 17-5. Cumulative incidences of relapse (A) and overall survival (B) in 147 
patients given nonmyeloablative HSCT after failed myeloablative HSCT according 
to diagnosis category group: HL, Hodgkin’s Lymphoma; MM, multiple myeloma; 
Myeloid, myeloid malignancies including acute myeloid leukemia (n=16), myelod-
ysplastic syndromes (n=12), chronic myeloid leukemia (n=3), and myeloproliferative 
disorders (n=2); NHL-A, aggressive Non-Hodgkin’s Lymphoma (n=24); NHL-I, indo-
lent Non-Hodgkin’s Lymphoma (n=12); NHL-MCL, mantle cell lymphoma (n=14) (C) 
Progression-free survival in 147 patients given nonmyeloablative HSCT after failed 
myeloablative HSCT according to disease status at HSCT Reprinted from F. Baron, 
et al., “Factors associated with outcomes in allogeneic hematopoietic cell transplanta-
tion with nonmyeloablative conditioning after failed myeloablative hematopoietic cell 
transplantation.” J Clin Oncol 2006; 24:4150–4157. Reprinted with permission from 
the American Society of Clinical Oncology”
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(P=0.05) and 50 percent (P=0.01), respectively, in the myeloablative group. 
Better overall survival was seen in the nonmyeloablative than in the myeloabla-
tive group at twoyears (39% versus 29%; P=0.056).
Scott, et al. compared results of allogeneic HSCT following either nonmy-
eloablative (2 Gy TBI with or without added fludarabine; n=38) or myeloabla-
tive (busulfan 16 mg/kg, targeted to 800–900 ng/mL and cyclophosphamide 
120 mg/kg, n=112) conditioning in patients with myelodysplastic syndrome 
over 40 years of age [47]. In multivariate analyses, three-year progression-
free survival (HR=1.1, P=0.60), progression incidence (HR=1.3, P=0.43) and 
non-relapse mortality (HR=1.0, P=0.94) were comparable between nonmyelo-
ablative and myeloablative patients. Further, in the subgroup of patients with 
transformed acute myeloid leukemia in morphological complete remission 
after chemotherapy, progression-free survival (HR=1, P=0.93) and progres-
sion rate (HR=0.7, P=0.64) were similar in patients given nonmyeloablative 
versus myeloablative conditioning. These observations suggest that Graft-versus-
Tumor effects are more important than conditioning intensity in preventing 
relapse in this group of patients.
Martino, et al. compared HSCT outcomes in 836 patients who received 
HLA-identical grafts from siblings at various EBMT-affiliated centers 
after nonmyeloablative (n=215) or myeloablative (n=621) conditioning 
[82]. Nonmyeloablative/reduced-intensity conditioning included fludara-
bine with intermediate doses of 1–2 alkylating agents (i.e., ≤ 10 mg/kg p.o. 
busulfan; ≤ 140 mg/m2 i.v. melphalan; or ≤ 10 mg/kg i.v. thiotepa) or low-dose 
(2–4 Gy) TBI. Three-year incidences of relapse, non-relapse mortality 
and progression-free survival were 45 percent, 22 percent and 33 percent, 
respectively, in nonmyeloablative recipients, versus 27 percent, 32 percent 
and 41 percent, respectively, in those given myeloablative conditioning. In 
multivariate analysis, nonmyeloablative recipients had a higher incidence of 
relapse (HR=1.64, P=0.001), but a lower incidence of non-relapse mortality 
(HR=0.61, P=0.015), leading to a similar probability of progression-free 
survival (P=0.9).
Aoudjhane, et al. analyzed data from 722 patients with de novo acute 
myeloid leukemia over 50 years of age and given allogeneic HSCT after either 
reduced-intensity (n=315) or myeloablative (n=407) conditioning among 
EBMT-affiliated centers [46]. Reduced-intensity conditioning regimens were 
defined as fludarabine combined with low-dose TBI (<3 Gy), or busulfan (total 
dose ≤ 8 mg/kg) or other nonmyeloablative drugs. Two-year probabilities 
of leukemia-free survival for patients in first complete remissions at HSCT 
(n=416) were 44 percent in patients given reduced-intensity conditioning 
versus 54 percent (P=0.26) in patients given myeloablative conditioning. For 
patients in second complete remissions at HSCT (n=104), the figures were 
55 percent versus 47 percent (P=0.81), respectively. In multivariate analyses, 
the use of reduced-intensity versus myeloablative conditioning was associated 
with a higher risk of relapse (RR 1.8, P=0.0003), a lower risk of non-relapse 
mortality (RR 0.48, P<0.0001) and comparable leukemia-free survival (RR 
1.15, P=0.24).
Finally, Dreger, et al. compared data from 155 patients with chronic lym-
phocytic leukemia who were given reduced-intensity conditioning after either 
reduced-intensity (n=73), or myeloablative conditioning (n=82) [83]. Two-year 
rates of relapse, non-relapse mortality and event-free survival were 28 percent, 
19 percent and 58 percent, respectively, in nonmyeloablative recipients, versus 
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11 percent, 26 percent and 62 percent, respectively, in those given myeloabla-
tive conditioning. In multivariate analysis, nonmyeloablative recipients had 
a higher incidence of relapse (HR=2.46, P=0.08), but a lower incidence of 
non-relapse mortality (HR=0.40, P=0.03), leading to a similar probability of 
event-free survival (HR=0.69, P=0.22).
Taken together, these studies suggest that nonmyeloablative/reduced-intensity 
conditioning achieved their goal of reducing early non-relapse mortality, but 
at the cost of a higher risk of relapse. Prospective studies comparing nonmy-
eloablative/reduced-intensity versus myeloablative conditioning are needed to 
define whether there is a role as well for nonmyeloablative/reduced-intensity 
conditioning in patients eligible for conventional myeloablative HSCT.
10. Impact of Comorbidities on the Selection 
of Conditioning Regimens
Since short-term results seem comparable in patients given either nonmyelo-
ablative or myeloablative conditioning, an important question is whether it is 
possible to determine which patients might benefit from a nonmyeloablative or 
reduced-intensity conditioning, and which others could safely receive myelo-
ablative regimens. In an effort to answer this question, Sorror, et al. assessed the 
effect of comorbidities (scored with the Hematopoietic Cell Transplantation-
specific comorbidity index (HCT-CI) [84]) on outcomes among patients with 
acute myeloid leukemia or myelodysplastic syndromes receiving allogeneic 
grafts after either nonmyeloablative (n=87) or myeloablative (n=360) con-
ditioning [85]. Survival for patients with low risk dis ase (defined as acute 
myeloid leukemia in first complete remission or myelodysplastic refractory-
anemia) and/or no/few comorbidities (HCT-CI scores of 0–1) was similar 
among the two groups. However, nonmyeloablative recipients with high risk 
disease and HCT-CI scores of ≥ 2 had less non-relapse mortality (HR=0.35, 
P=0.006), and better overall survival (HR=0.55, P=0.01) than comparable 
patients given myeloablative conditioning, suggesting that nonmyeloablative 
conditioning should be preferentially used in such patients.
The same group investigated the impact of comorbidities on HSCT out-
comes in patients with B-cell malignancies given allogeneic HSCT after either 
nonmyeloablative or myeloablative conditioning [86]. Among patients with-
out comorbidity at HSCT (HCT-CI = 0), survival was comparable for patients 
given nonmyeloablative or myeloablative conditioning (P=0.7). In contrast, 
among patients with comorbidities (HCT-CI score ≥ 1) at HSCT, the use of 
nonmyeloablative conditioning was associated with lower non-relapse mortality 
(HR=0.5, P=0.03) and better overall survival (HR=0.6, P=0.05).
11. Does Nonmyeloablative HSCT Improve Survival 
over Chemotherapy in Patients with Hematological 
Malignancies?
It has been difficult to compare the results of phase I–II studies assessing non-
myeloablative/reduced-intensity conditioning to those obtained in comparable 
patients given conventional chemotherapy, since one could argue that only 
fitter patients were referred to transplantation centers and offered HSCT. This 
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underlines the interest of analyses comparing outcomes in patients who have 
an HLA-identical sibling donor (and could potentially receive a HSCT) in 
comparison to those who do not.
11.1 Acute Myeloid Leukemia
Mohty, et al. investigated whether allogeneic HSCT after reduced-intensity 
conditioning improved progression-free survival in adults with newly diag-
nosed acute myeloid leukemia who achieved complete remissions after induction 
chemotherapy, but were ineligible for conventional HSCT because of age or 
medical comorbidities [87]. Ninety-five consecutive patients {median age 52 
(range, 26–65) years old} were retrospectively analyzed. Thirty-five patients 
had HLA-identical sibling donors (donor group), while 60 did not (no donor 
group). Twenty-five of 35 patients included in the donor group (71%) could 
received the allogeneic HSCT, while 10 patients with an identified donor did 
not receive allogeneic HSCT because of patient or donor refusals (n=6), early 
relapse (n=2) or psychiatric disorders (n=2). The four-year probability of pro-
gression-free survival was 54 percent in the donor group, versus 30 percent in 
the non-donor group (P=0.01). This was due to a significantly lower risk of 
relapse in patients who received an allogeneic HSCT (12% at four years), than 
in those who did not (54% at four years, P<0.001).
The Groupe Ouest Est d’Etude des Leucémies et Autres Maladies du Sang 
(GOELAMS) recently reported the first results of a phase III study comparing 
outcomes of patients with acute myeloid leukemia in first complete remission 
receiving either autologous or allogeneic HSCT [88]. A search to identify 
an HLA-identical sibling was performed for each patient as they received a 
first course of consolidation therapy. After a second course of consolidation 
chemotherapy, patients with an HLA-matched sibling donor were scheduled 
to undergo an HSCT after either myeloablative (if age ≤ 50; consisting of 
12 Gy TBI and cyclophosphamide 120 mg/kg) or reduced-intensity (if age 
51–60; consisting of busulfan 4–8 mg/kg, fludarabine 120 mg/m2, and ATG) 
conditioning. Among patients younger that 50 years, disease free survival was 
significantly better in patients included in the allogeneic arm (n=111), than 
in those included in the autologous arm (71% versus 52%, P=0.007). Among 
patients aged 50- to 60-years-old, there was better disease free survival in 
patients given reduced-intensity allogeneic HSCT, than in those given autolo-
gous HSCT (62% versus 50%, P=0.27).
11.2. Multiple Myeloma
The Intergroupe Francophone du Myelome compared autologous HSCT 
followed by dose-reduced allograft (n=65) with tandem autologous HSCT 
(n=219) in high risk de novo multiple myeloma (defined as deletion 13 and/or 
β2 microglobulin >3 mg/L) [89]. The reduced-intensity conditioning regimen 
consisted of busulfan (4 mg/kg), fludarabine (125 mg/m2) and ATG (Imtix; 
12.5 mg/kg). Nineteen of the 65 patients with a sibling donor did not receive 
the allogeneic HSCT because of progressive disease (n=7), donor/patient 
refusal (n=5), ongoing infection (n=4) or unknown causes (n=3). On an intent-
to-treat basis, survival (P=0.27) and event-free survival (P=0.56) did not differ 
between studies. However, the lack of improved survival in the allogeneic arm 
might be due to the high-dose ATG used that abrogated Graft-versus-Tumor 
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effects. Further, the choice of including busulfan instead of melphalan in the 
conditioning regimen was controversial. Indeed, the use of busulfan in the con-
ditioning regimen was associated with inferior survival (P=0.01) in the multiple 
myeloma EBMT study [49]. Results of the ongoing BMT-CTN 01–02 mul-
tiple myeloma study will help to better define the role for nonmyeloablative 
HSCT in patients with multiple myeloma.
12. Conclusions and Perspectives
Reduced-intensity conditioning and nonmyeloablative regimens have allowed 
older patients, those who had failed a high-dose HSCT, and those with comor-
bidity to benefit from the potentially curative Graft-versus-Tumor effects. 
Remarkably, minimally toxic regimens of 2 Gy TBI with or without fludarab-
ine, or TLI plus ATG each followed by post-grafting immunosuppression with 
MMF and CSP have assured engraftment rates almost similar to those after 
myeloablative conditioning [15, 20] . Antitumor responses in some disease 
types require extended periods of time, with some patients achieving complete 
remissions more than one year after HSCT [15, 54] .
Ongoing efforts are directed at better preventing acute GVHD, at increasing 
the use of nonmyeloablative regimens in patients given haploidentical grafts [90] 
or unrelated cord blood [91] and at increasing Graft-versus-Tumor effects by 
combining nonmyeloablative conditioning with disease-targeted therapy such 
as imatinib, thalidomide, bortezomib, rituximab or radiolabeled monoclonal 
antibodies [63, 92–95] . For example, encouraging results have been achieved 
by combining the anti-CD45 radiolabeled monoclonal antibody with nonmyelo-
ablative conditioning in patients with acute myeloid leukemia not in complete 
remission at HSCT or with advanced myelodysplastic syndromes [93]. Other 
groups of investigators are focusing on identifying patients at high risk of relapse 
early after HSCT and treating them with preemptive DLI or rapid taper of post-
grafting immunosuppression [29]. Finally, further progress in adoptive transfer 
of T cell populations with relative tumor specificity are likely to improve HSCT’s 
effectiveness after reduced-intensity or nonmyeloablative regimens [96].
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